KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) EPS (Weighted Average and Diluted) (2020 - 2025)

Royalty Pharma's EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at $0.5 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 6.38% year-over-year to $0.5; the TTM value through Dec 2025 reached $1.78, down 6.81%, while the annual FY2025 figure was $1.78, 6.81% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.5 at Royalty Pharma, down from $0.66 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.2 in Q3 2024 and bottomed at -$1.04 in Q4 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is $0.4 (2024), against an average of $0.39.
  • The largest annual shift saw EPS (Weighted Average and Diluted) tumbled 10300.0% in 2022 before it soared 5400.0% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.01 in 2021, then crashed by 10300.0% to -$1.04 in 2022, then surged by 206.73% to $1.11 in 2023, then tumbled by 57.66% to $0.47 in 2024, then increased by 6.38% to $0.5 in 2025.
  • Per Business Quant, the three most recent readings for RPRX's EPS (Weighted Average and Diluted) are $0.5 (Q4 2025), $0.66 (Q3 2025), and $0.07 (Q2 2025).